Papers/PMID:41097174
Bifidobacterium animalis subsp. lactis TISTR 2591 Improves Glycemic Control and Immune Response in Adults with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial.
Nutrients2025The record
2 findings · 1 compound · 2 endpoints · 1 null
What it reported
How to read these marksWhat moved
1 finding
Bifidobacterium animalis — decreases total antioxidant capacity
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Plasma total antioxidant status, assessed as Trolox Equivalent Antioxidant Capacity (TEAC), declined modestly in the probiotic group (Δ = −0.004 mg TE/mL) and increased in the placebo group (Δ = +0.002 mg TE/mL), with a significant intergroup difference (p < 0.001).”
Quoted verbatim from Bifidobacterium animalis subsp. lactis TISTR 2591 Improves Glycemic Control and Immune Response in Adults with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial.. - Study
- crossover
- Duration
- 6 weeks
- Dose
- three 350 mg capsules daily (1050 mg), guaranteed minimum 1 x 10^9 CFU/g
- Population
- Thai adults aged 35 to 65 with type 2 diabetes mellitus on metformin monotherapy in both phases; 6-week probiotic and placebo phases with 4-week washout
Bifidobacterium animalis subsp. lactis TISTR 2591 Improves Glycemic Control and Immune Response in Adults with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial.2025PMID:41097174Permalink
What did not
1 finding
Bifidobacterium animalis — no detected effect on C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“In this study, hs-CRP levels slightly decreased in the probiotic group (2.94 ± 3.74 to 2.89 ± 3.09 mg/L; Δ = −0.053) and increased in the placebo group (2.94 ± 3.29 to 3.20 ± 3.45 mg/L; Δ = +0.271), with no significant intergroup difference (p = 0.213).”
Quoted verbatim from Bifidobacterium animalis subsp. lactis TISTR 2591 Improves Glycemic Control and Immune Response in Adults with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial.. - Study
- crossover
- Duration
- 6 weeks
- Dose
- three 350 mg capsules daily (1050 mg), guaranteed minimum 1 x 10^9 CFU/g
- Population
- Thai adults aged 35 to 65 with type 2 diabetes mellitus on metformin monotherapy in both phases; 6-week probiotic and placebo phases with 4-week washout
Bifidobacterium animalis subsp. lactis TISTR 2591 Improves Glycemic Control and Immune Response in Adults with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial.2025PMID:41097174Permalink